Thursday, 15 October 2026European Markets

RALLYE Stock Over 9% Up So Far On Friday

Loading stream...

(vianews) - shares of rallye (cac 40: ral.pa) jumped 9.98% to €0.93 at 11:05 est on friday, following the last session's upward trend. cac 40 is jumping 0.13% to €7,394.38, after three consecutive sessions in a row of gains. this seems, so far, a somewhat positive trend exchanging session today.

rallye's last close was €0.81, 77.44% under its 52-week high of €3.60.

about rallye

rallye sa, together with its subsidiaries, engages in the food and non-food e-commerce retailing business in france and internationally. the company operates in two segments, food and general retailing, and holdings and other activities. it operates hypermarkets, supermarkets, and convenience stores. the company conducts its retailing activities in france primarily under the casino, monoprix, and franprix banners; food retail activities in brazil, colombia, uruguay, and argentina mainly under the gpa food banners, éxito, disco-devoto, and libertad banners; and e-commerce comprising cdiscount and the cnova n.v. holding company businesses. it is also involved in the financial investment, property development, and energy related activities. the company was founded in 1925 and is headquartered in paris, france. rallye sa is a subsidiary of foncière euris sa.

earnings per share

as for profitability, rallye has a trailing twelve months eps of €-4.17.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -9.93%.

more news about rallye (ral.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com